The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models

Adam L. Knight, Xiaohui Yan, Shusei Hamamichi, Rami R. Ajjuri, Joe Mazzulli, Mike W. Zhang, J. Gavin Daigle, Siyuan Zhang, Akeem R. Borom, Lindsay R. Roberts, S. Kyle Lee, Susan M. DeLeon, Coralie Viollet-Djelassi, Dimitri Krainc, Janis M. O'Donnell, Kim A. Caldwell, Guy A. Caldwell*

*Corresponding author for this work

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Neurodegenerative diseases represent an increasing burden in our aging society, yet the underlying metabolic factors influencing onset and progression remain poorly defined. The relationship between impaired IGF-1/insulin-like signaling (IIS) and lifespan extension represents an opportunity to investigate the interface of metabolism with age-associated neurodegeneration. Using data sets of established DAF-2/IIS-signaling components in Caenorhabditis elegans, we conducted systematic RNAi screens in worms to select for daf-2-associated genetic modifiers of α-synuclein misfolding and dopaminergic neurodegeneration, two clinical hallmarks of Parkinson's disease. An outcome of this strategy was the identification of GPI-1/GPI, an enzyme in glucose metabolism, as a daf-2-regulated modifier that acts independent of the downstream cytoprotective transcription factor DAF-16/FOXO to modulate neuroprotection. Subsequent mechanistic analyses using Drosophila and mouse primary neuron cultures further validated the conserved nature of GPI neuroprotection from α-synuclein proteotoxicity. Collectively, these results support glucose metabolism as a conserved functional node at the intersection of proteostasis and neurodegeneration.

Original languageEnglish (US)
Pages (from-to)145-157
Number of pages13
JournalCell Metabolism
Volume20
Issue number1
DOIs
StatePublished - Jul 1 2014

Fingerprint

Synucleins
Insulin-Like Growth Factor I
Enzymes
Insulin
Glucose
Caenorhabditis elegans
RNA Interference
Neurodegenerative Diseases
Drosophila
Parkinson Disease
Transcription Factors
Neurons
Neuroprotection

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Cell Biology

Cite this

Knight, Adam L. ; Yan, Xiaohui ; Hamamichi, Shusei ; Ajjuri, Rami R. ; Mazzulli, Joe ; Zhang, Mike W. ; Daigle, J. Gavin ; Zhang, Siyuan ; Borom, Akeem R. ; Roberts, Lindsay R. ; Lee, S. Kyle ; DeLeon, Susan M. ; Viollet-Djelassi, Coralie ; Krainc, Dimitri ; O'Donnell, Janis M. ; Caldwell, Kim A. ; Caldwell, Guy A. / The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models. In: Cell Metabolism. 2014 ; Vol. 20, No. 1. pp. 145-157.
@article{29eeed8b9ba64fe09512e1741d786583,
title = "The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models",
abstract = "Neurodegenerative diseases represent an increasing burden in our aging society, yet the underlying metabolic factors influencing onset and progression remain poorly defined. The relationship between impaired IGF-1/insulin-like signaling (IIS) and lifespan extension represents an opportunity to investigate the interface of metabolism with age-associated neurodegeneration. Using data sets of established DAF-2/IIS-signaling components in Caenorhabditis elegans, we conducted systematic RNAi screens in worms to select for daf-2-associated genetic modifiers of α-synuclein misfolding and dopaminergic neurodegeneration, two clinical hallmarks of Parkinson's disease. An outcome of this strategy was the identification of GPI-1/GPI, an enzyme in glucose metabolism, as a daf-2-regulated modifier that acts independent of the downstream cytoprotective transcription factor DAF-16/FOXO to modulate neuroprotection. Subsequent mechanistic analyses using Drosophila and mouse primary neuron cultures further validated the conserved nature of GPI neuroprotection from α-synuclein proteotoxicity. Collectively, these results support glucose metabolism as a conserved functional node at the intersection of proteostasis and neurodegeneration.",
author = "Knight, {Adam L.} and Xiaohui Yan and Shusei Hamamichi and Ajjuri, {Rami R.} and Joe Mazzulli and Zhang, {Mike W.} and Daigle, {J. Gavin} and Siyuan Zhang and Borom, {Akeem R.} and Roberts, {Lindsay R.} and Lee, {S. Kyle} and DeLeon, {Susan M.} and Coralie Viollet-Djelassi and Dimitri Krainc and O'Donnell, {Janis M.} and Caldwell, {Kim A.} and Caldwell, {Guy A.}",
year = "2014",
month = "7",
day = "1",
doi = "10.1016/j.cmet.2014.04.017",
language = "English (US)",
volume = "20",
pages = "145--157",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "1",

}

Knight, AL, Yan, X, Hamamichi, S, Ajjuri, RR, Mazzulli, J, Zhang, MW, Daigle, JG, Zhang, S, Borom, AR, Roberts, LR, Lee, SK, DeLeon, SM, Viollet-Djelassi, C, Krainc, D, O'Donnell, JM, Caldwell, KA & Caldwell, GA 2014, 'The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models', Cell Metabolism, vol. 20, no. 1, pp. 145-157. https://doi.org/10.1016/j.cmet.2014.04.017

The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models. / Knight, Adam L.; Yan, Xiaohui; Hamamichi, Shusei; Ajjuri, Rami R.; Mazzulli, Joe; Zhang, Mike W.; Daigle, J. Gavin; Zhang, Siyuan; Borom, Akeem R.; Roberts, Lindsay R.; Lee, S. Kyle; DeLeon, Susan M.; Viollet-Djelassi, Coralie; Krainc, Dimitri; O'Donnell, Janis M.; Caldwell, Kim A.; Caldwell, Guy A.

In: Cell Metabolism, Vol. 20, No. 1, 01.07.2014, p. 145-157.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models

AU - Knight, Adam L.

AU - Yan, Xiaohui

AU - Hamamichi, Shusei

AU - Ajjuri, Rami R.

AU - Mazzulli, Joe

AU - Zhang, Mike W.

AU - Daigle, J. Gavin

AU - Zhang, Siyuan

AU - Borom, Akeem R.

AU - Roberts, Lindsay R.

AU - Lee, S. Kyle

AU - DeLeon, Susan M.

AU - Viollet-Djelassi, Coralie

AU - Krainc, Dimitri

AU - O'Donnell, Janis M.

AU - Caldwell, Kim A.

AU - Caldwell, Guy A.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Neurodegenerative diseases represent an increasing burden in our aging society, yet the underlying metabolic factors influencing onset and progression remain poorly defined. The relationship between impaired IGF-1/insulin-like signaling (IIS) and lifespan extension represents an opportunity to investigate the interface of metabolism with age-associated neurodegeneration. Using data sets of established DAF-2/IIS-signaling components in Caenorhabditis elegans, we conducted systematic RNAi screens in worms to select for daf-2-associated genetic modifiers of α-synuclein misfolding and dopaminergic neurodegeneration, two clinical hallmarks of Parkinson's disease. An outcome of this strategy was the identification of GPI-1/GPI, an enzyme in glucose metabolism, as a daf-2-regulated modifier that acts independent of the downstream cytoprotective transcription factor DAF-16/FOXO to modulate neuroprotection. Subsequent mechanistic analyses using Drosophila and mouse primary neuron cultures further validated the conserved nature of GPI neuroprotection from α-synuclein proteotoxicity. Collectively, these results support glucose metabolism as a conserved functional node at the intersection of proteostasis and neurodegeneration.

AB - Neurodegenerative diseases represent an increasing burden in our aging society, yet the underlying metabolic factors influencing onset and progression remain poorly defined. The relationship between impaired IGF-1/insulin-like signaling (IIS) and lifespan extension represents an opportunity to investigate the interface of metabolism with age-associated neurodegeneration. Using data sets of established DAF-2/IIS-signaling components in Caenorhabditis elegans, we conducted systematic RNAi screens in worms to select for daf-2-associated genetic modifiers of α-synuclein misfolding and dopaminergic neurodegeneration, two clinical hallmarks of Parkinson's disease. An outcome of this strategy was the identification of GPI-1/GPI, an enzyme in glucose metabolism, as a daf-2-regulated modifier that acts independent of the downstream cytoprotective transcription factor DAF-16/FOXO to modulate neuroprotection. Subsequent mechanistic analyses using Drosophila and mouse primary neuron cultures further validated the conserved nature of GPI neuroprotection from α-synuclein proteotoxicity. Collectively, these results support glucose metabolism as a conserved functional node at the intersection of proteostasis and neurodegeneration.

UR - http://www.scopus.com/inward/record.url?scp=84904035981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904035981&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2014.04.017

DO - 10.1016/j.cmet.2014.04.017

M3 - Article

VL - 20

SP - 145

EP - 157

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 1

ER -